Skip to main content
Publications
Abtahi S, Pajouheshnia R, Duran CE, Riera-Arnau J, Gamba M, Alsina E, Hoxhaj V, Andersen M, Bartolini C, Kristiansen SB, Brown J, Hallgreen CE, Garcia-Poza P, Gardarsdottir H, Gini R, Girardi A, Holthuis E, Huerta C, Ibanez L, Limoncella G, Martin-Perez M, Paoletti O, Roberto G, Souverein P, Swart KMA, Wing K, Sturkenboom M, Klungel O. Impact of 2018 EU Risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study. Drug Saf. 2023 Jul;46(7):689-702. doi: 10.1007/s40264-023-01314-3
Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3
Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4
Beier L, Lu S, Franca LR, Marler S, Lip GYH, Huisman MV, Teutsch C, Halperin JL, Zint K, Diener HC, Baker L, Ma CS, Paquette M, Bartels DB, Dubner SJ, Lyrer P, Senges J, Rothman KJ. Evolution of antithrombotic therapy for patients with atrial fibrillation: the prospective global GLORIA-AF registry program. PLoS One. 2022 Oct 6;17(10):e0274237. doi: 10.1371/journal.pone.0274237
Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Holthuis E, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot Consortium Members of the Valproate study. Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of valproates. Poster presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1312-3. doi: 10.1007/s40264-022-01219-7
Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot4 Consortium Members of the Valproate study1. Impact of the 2018 pregnancy prevention program on the use of oral retinoids in childbearing age females in Europe. Presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1111-327. doi: 10.1007/s40264-022-01219-7
Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0
Ersbøll AK, Sengupta K, Pukkala E, Bolin K, Aas E, Emneus M, Ramey DR, Brady JE, Mines D, Aasbjerg K, Vestergaard C, Gislason G, Born AP, Kjærulff TM. Desloratadine exposure and incidence of seizure: a nordic post-authorization safety study using a new-user cohort study design, 2001-2015. Drug Saf. 2021 Nov;44(11):1231-42. doi: 10.1007/s40264-021-01106-7
Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7
Koziel M, Teutsch C, Halperin JL, Rothman KJ, Diener HC, Ma CS, Marler S, Lu S, Gurusamy VK, Huisman MV, Lip GYH, GLORIA-AF Investigators. Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF. PLoS One. 2021 Apr 14;16(4):e0249524. doi: 10.1371/journal.pone.0249524
Bedard A, Carsin AE, Fuertes E, Accordini S, Dharmage SC, Garcia-Larsen V, Heinrich J, Janson C, Johannessen A, Leynaert B, Sanchez-Ramos JL, Peralta GP, Pin I, Squillacioti G, Weyler J, Jarvis D, Garcia-Aymerich J. Physical activity and lung function-cause or consequence? PLoS One. 2020 Aug 20;15(8):e0237769. doi: 10.1371/journal.pone.0237769
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0
Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z
Fuertes E, Carsin AE, Garcia-Larsen V, Guerra S, Pin I, Leynaert B, Accordini S, Martinez-Moratalla J, Anto JM, Urrutia I, Le Gouellec A, Heinrich J, Gislason T, Jogi R, Janson C, Jarvis D, Garcia-Aymerich J. The role of C-reactive protein levels on the association of physical activity with lung function in adults. PLoS One. 2019 Sep 23;14(9):e0222578. doi: 10.1371/journal.pone.0222578
Peay H, Fischer R, Tzeng JP, Hesterlee SE, Morris C, Martin AS, Rensch C, Smith E, Ricotti V, Beaverson K, Wand H, Mansfield C. Gene therapy as a potential therapeutic option for Duchenne muscular dystrophy: a qualitative preference study of patients and parents. PLoS One. 2019 May 1;14(5):e0213649. doi: 10.1371/journal.pone.0213649
Margulis AV, Linder M, Arana A, Pottegard A, Berglind IA, Bui CL, Kristiansen NS, Bahmanyar S, McQuay LJ, Atsma WJ, Appenteng K, D'Silva M, Perez-Gutthann S, Hallas J. Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. 2018 Sep 27;13(9):e0204456. doi: 10.1371/journal.pone.0204456
Turino C, Bertran S, Gavalda R, Teixido I, Woehrle H, Rue M, Solsona F, Escarrabill J, Colls C, Garcia-Altes A, de Batlle J, Sanchez de-la-Torre M, Barbe F. Characterization of the CPAP-treated patient population in Catalonia. PLoS One. 2017 Sep 21;12(9):e0185191. doi: 10.1371/journal.pone.0185191
Triguero-Mas M, Gidlow CJ, Martinez D, de Bont J, Carrasco-Turigas G, Martinez-Iniguez T, Hurst G, Masterson D, Donaire-Gonzalez D, Seto E, Jones MV, Nieuwenhuijsen MJ. The effect of randomised exposure to different types of natural outdoor environments compared to exposure to an urban environment on people with indications of psychological distress in Catalonia. PLoS One. 2017 Mar 1;12(3):e0172200.
Liu X, Behrman JR, Stein AD, Adair LS, Bhargava SK, Borja JB, da Silveira MF, Horta BL, Martorell R, Norris SA, Richter LM, Sachdev HS. Prenatal care and child growth and schooling in four low- and medium-income countries. PLoS One. 2017 Feb 3;12(2):e0171299. doi: 10.1371/journal.pone.0171299
Saigi-Morgui N, Quteineh L, Bochud PY, Crettol S, Kutalik Z, Wojtowicz A, Bibert S, Beckmann S, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Swiss Transplant Cohort Study. Weighted genetic risk scores and prediction of weight gain in solid organ transplant populations. PLoS One. 2016 Oct 27. doi: 10.1371/journal.pone.0164443
Delacretaz A, Preisiq M, Vandenberghe F, Saigi Morgui N, Quteineh L, Choong E, Gholam-Rezaee M, Kutalik Z, Magistretti P, Aubry JM, von Gunten A, Castelao E, Vollenweider P, Waeber G, Conus P, Eap CB. Influence of MCHR2 and MCHR2-AS1 genetic polymorphisms on body mass index in psychiatric patients and in population-based subjects with present or past atypical depression. PLoS One. 2015 Oct 13;10(10):e0139155. doi: 10.1371/journal.pone.0139155
Eze IC, Schaffner E, Foraster M, Imboden M, von Eckardstein A, Gerbase MW, Rothe T, Rochat T, Kunzli N, Schindler C, Probst-Hensch N. Long-term exposure to ambient air pollution and metabolic syndrome in adults. PLoS One. 2015 Jun 23;10(6):e0130337. doi: 10.1371/journal.pone.0130337
Schmiedl S, Fischer R, Ibanez L, Fortuny J, Klungel OH, Reynolds R, Gerlach R, Tauscher M, Thurmann P, Hasford J, Rottenkolber M. Utilisation and off-label prescriptions of respiratory drugs in children. PLoS One. 2014 Sep 2;9(9):e105110. doi: 10.1371/journal.pone.0105110
Fernandez-Aranda F, Sauchelli S, Pastor A, Gonzalez ML, de la Torre R, Granero R, Jimenez-Murcia S, Banos R, Botella C, Fernandez-Real JM, Fernandez-Garcia JC, Fruhbeck G, Gomez-Ambrosi J, Rodriguez R, Tinahones FJ, Arcelus J, Fagundo AB, Aguera Z, Miro J, Casanueva FF. Moderate-vigorous physical activity across body mass index in female: moderating effect of endocannabinoids and temperament. PLoS One. 2014 Aug 7;9(8):e104534. doi: 10.1371/journal.pone.0104534